August 5, 2021 C-Path Appoints Clinical Outcome Assessment Expert as New Executive Director Sonya Eremenco will lead C-Path’s PRO Consortium TUCSON, Ariz., August 5, 2021— Critical Path Institute (C-Path) announced it
July 20, 2021 Digital Health Technologies Hold Key to New Parkinson’s Treatments Global stakeholders come together to collaborate with urgency to address unmet needs for Parkinson’s therapies. TUCSON, Ariz., J
July 15, 2021 Launch of UNITE4TB Partnership Marks a New Era in Tuberculosis Treatment Development The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiat
July 8, 2021 C-Path Announces Health Care Leader Appointment to Board of Directors TUCSON, Ariz., July 8, 2021 — Critical Path Institute (C-Path) today announced the appointment of health care industry leader
June 24, 2021 Clinical Technology Expert and Experienced Neuroscientist Join C-Path in Executive Director Roles Scottie Kern and Dr. Terina N. Martínez Will Both Serve in Dual Positions TUCSON, Ariz., June 24, 2021 — Critical Path Instit
May 25, 2021 C-Path Virtual Workshop to Feature Latest Advances in Clinical Trials for T1D More than 300 Attendees and 20 Speakers Are Expected to Participate in the International Workshop, June 15-16 TUCSON, Ariz., May 2
May 12, 2021 C-Path Announces Accelerated Data Sharing Collaboration with Tufts Medical Center FDA Grant Supports Use of Real-World Data to Generate Real-World Evidence in Neonates TUCSON, Ariz., May 12, 2021 — Criti
May 6, 2021 C-Path Appoints Quantitative Sciences Expert as New Sr. Vice President Dr. Jeff Barrett will lead C-Path’s RDCA-DAP initiative focusing on rare disease data sharing and accelerating therapy devel
April 26, 2021 C-Path Selects New Leaders of Data Science and Quantitative Medicine TUCSON, Ariz., April 26, 2021 — Critical Path Institute (C-Path) has named Amanda J. Borens, M.S., as Executive Director of Data
April 22, 2021 C-Path Opens Access to Duchenne Regulatory Science Consortium Database Database will allow sharing of individual-level data with the goal of accelerating therapy development for Duchenne muscular dystr